The GLP-1 Market is being shaped by clinical innovation, demographic change, and evolving supply and regulatory conditions. Valued at USD 52.82 billion in 2025, the GLP-1 Market is projected to reach USD 58.48 billion in 2026 and USD 133.92 billion by 2034, growing at a CAGR of 10.9% during the forecast period 2026–2034. Key players include AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical.

Demographics and Guidelines Support GLP-1 Analogues

Older adults are highly prone to type 2 diabetes and related conditions, and they increasingly require therapies that deliver glycemic control, weight reduction, and broader cardiometabolic support. According to the UN, the global population aged 65 years and above is expected to rise from 761 million in 2021 to 1.6 billion by 2050. ADA guidance also notes benefits of GLP-1 therapies for diabetes patients who also have cardiovascular disease, chronic kidney disease, or obesity-linked complications. Clinical guidelines from the American Diabetes Association and the European Association for the Study of Diabetes support the use of GLP-1 analogues in specific patient populations, which promotes broader prescribing across the GLP-1 Market. The ADA's 2026 Standards are expanding the relevance of GLP-1-based therapies in diabetes, obesity, and related metabolic care.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/glp-1-market

Dual Incretin Therapies and the GLP-1 Pipeline

Ongoing research and development is bringing next-generation therapies, oral formulations, and dual incretin therapies toward commercialization. The GLP-1 pipeline spans obesity, diabetes, and cardiometabolic indications, with candidates advancing through clinical stages as of March 2026. Eli Lilly's orforglipron is in Phase 3 for type 2 diabetes, and Boehringer Ingelheim's survodutide, a GLP-1/glucagon agonist, is in Phase 3 for metabolic dysfunction-associated steatohepatitis and obesity. Novo Nordisk's CagriSema is in Phase 3 and, per a December 2025 announcement, has been filed for FDA approval for obesity. Hanmi Pharmaceutical's efpeglenatide is in Phase 3, AstraZeneca's oral candidate elecoglipron is in Phase 2, and Roche's CT-388, a GLP-1/GIP dual agonist, has completed Phase 2. Pfizer's PF-3944 (MET-097i) is in Phase 2b for chronic weight management, D&D Pharmatech's DD01, a GLP-1/glucagon dual agonist, is in Phase 2 for MASH, and Tonghua Dongbao's THDBH120, a GLP-1/GIP dual agonist, has completed Phase 1b for weight loss. Target indications now extend to Alzheimer's disease, non-alcoholic steatohepatitis, sleep apnea, and obesity alongside diabetes.

GLP-1 Drug Shortage and Compounded Product Regulation

A GLP-1 drug shortage has persisted since late 2022, prompting major manufacturers to significantly expand global production and manufacturing capacity. Regulatory restrictions on compounded GLP-1 drugs limit unapproved alternatives, strengthening demand for branded products, ensuring safety standards, and improving revenue prospects for approved manufacturers. Other risks include safety concerns and side effects, strict regulatory scrutiny, high treatment costs, supply constraints, and increasing competition from new obesity and diabetes therapies. Patent expiries are creating opportunities for generics. Economic and geopolitical changes, including pricing pressures and regulatory policies, are also affecting vendor strategies and driving partnerships.

Partnerships and Industry Developments Create Opportunity

Partnerships, product launches, and personalized medicine are creating lucrative opportunities, and leading pharmaceutical companies collaborate to improve R&D efficiency and bring new therapies to market more quickly. In May 2025, UK-based CheqUp and WeightWatchers teamed up to offer clinical GLP-1 medication support alongside behavioral lifestyle programs, delivering integrated weight management. In May 2025, Illumina and Ovation.io developed a clinical multiomic dataset from 25,000 GLP-1 therapy patients to support drug discovery. In February 2025, Biocon launched liraglutide in the UK under two brand names, Liraglutide Biocon for diabetes and Biolide for chronic weight management.

Regionally, Asia Pacific is projected to see the fastest growth, supported by pharmaceutical investment, improved affordability, and local production initiatives, while North America remains the largest market. Rising research, development, and collaborations to extend GLP-1 applications are emerging as key market trends. Sustainable value chains and pricing insights are becoming key factors as payers focus on cost-effectiveness across the GLP-1 Market.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market